Authored By: Sarah
11 Jul 2024

 Head And Neck Cancer Diagnostics Market Size to grow by USD 6302.9 million between 2024-2028

According to a research report “ Head And Neck Cancer Diagnostics Market” by Diagnostic Methods (Biopsy and blood tests, Imaging, Endoscopy, Dental diagnostics) End-user (Hospitals, Specialty clinics, Ambulatory surgical centers, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 6302.9 million, at a CAGR of  13.64% during the forecast period. Head and neck cancers represent a significant segment of the global cancer market, accounting for approximately 4% of all cancer cases in the United States as of January 2023. These cancers affect various regions, including the oral cavity, pharynx (nasopharynx, oropharynx, and hypopharynx), larynx, paranasal sinuses and nasal cavity, and salivary glands. The majority of head and neck cancers are attributed to Squamous Cell Carcinoma (SCC), which is prevalent among men with a history of alcohol consumption and tobacco use. HNSCC (Head and Neck Squamous Cell Carcinoma) develops around the mucosal linings of the upper aerodigestive tract. With about half a million new cases diagnosed globally each year, HNSCC ranks as the sixth-leading cancer by incidence. Effective diagnostics are crucial to improve early detection and prognosis for this disease.

Browse market data tables, figures, and in-depth TOC on “Head And Neck Cancer Diagnostics Market” by Diagnostic Methods (Biopsy and blood tests, Imaging, Endoscopy, Dental diagnostics) End-user (Hospitals, Specialty clinics, Ambulatory surgical centers, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Diagnostic Methods, the Biopsy and blood tests segment is projected to dominate the market size in 2024

The head and neck cancer diagnostics market is experiencing notable growth within the hospital segment, projected to exhibit a robust CAGR during the forecast period. This expansion is attributed to the advantages offered by head and neck cancer diagnostic methods to hospitals and clinics. These benefits include enhanced patient care and satisfaction, operational efficiencies at Point of Care (POC), and cost savings that bolster the bottom line. In 2021, hospitals emerged as the primary contributors to market growth, driven by the increasing incidence of chronic diseases and the availability of skilled professionals.

By End-user, Hospitals  segment is expected to hold the largest market size for the year 2024

The Head and Neck Cancer Diagnostics Market represents a significant business opportunity due to the rising prevalence of head and neck cancers worldwide. Advanced diagnostic tools, such as CT scans, MRI, and PET-CT scans, are driving market growth. Early and accurate diagnosis is crucial for effective treatment and improving patient outcomes. Market players are investing in research and development to introduce innovative diagnostic solutions, thereby expanding their market presence.

North America is forecasted to hold the largest market size by region in 2024

The Head and Neck Cancer Diagnostics Market represents a significant business opportunity due to the rising incidence of head and neck malignancies worldwide. Advanced diagnostic tools, such as CT scans, MRI, and PET-CT scans, are driving market growth. These technologies enable early detection, improving patient outcomes and survival rates. Additionally, increasing government funding and private investments in cancer research further boost market expansion.

The Head And Neck Cancer Diagnostics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Accuray Inc.
  • AdDent Inc.
  • Bristol Myers Squibb Co.
  • Canon Inc.
  • Carestream Health Inc.
  • Eli Lilly and Co.
  • Esaote Spa
  • Flexicare Group Ltd.
  • General Electric Co.
  • Hitachi Ltd.
  • KARL STORZ SE and Co. KG
  • Koninklijke Philips N.V.
  • Merck KGaA
  • Olympus Corp.
  • Optim LLC
  • Shimadzu Corp.
  • Siemens AG
  • Sumitomo Mitsui Financial Group
  • Xoran Technologies LLC
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Head and neck cancer, including throat and oropharyngeal cancer, is a significant global health concern. Early detection is crucial for effective treatment and improving patient outcomes. Dental care plays a vital role in identifying potential signs of head and neck cancer, as many cases are first detected during routine dental check-ups. The Head and Neck Cancer Diagnostics Market is witnessing growth due to rising healthcare expenditure, both from personal and hospital sources. Prescription drugs and diagnostic devices are driving market expansion. Novel technologies, such as PET/CT, CT, MRI, endoscopy, and diagnostic imaging, are increasingly being used for accurate diagnosis. Physical exams, biopsies, and pathologists' evaluations remain essential diagnostic procedures. Radiologists and oncologists collaborate to interpret imaging results. Cancer centers specialize in head and neck cancer diagnosis and treatment, offering advanced diagnostic services. Healthcare expenditure on cancer worldwide continues to rise. In the US, hospital spending on cancer care is projected to reach USD173 billion by 2027. Personal healthcare spending on prescription drugs and diagnostic procedures is also increasing. In conclusion, the Head and Neck Cancer Diagnostics Market is growing due to the rising burden of cancer, increasing healthcare expenditure, and advancements in diagnostic technologies. Early detection through dental care and specialized diagnostic procedures plays a crucial role in effective treatment and improving patient outcomes.

Market Research Overview

Head and neck cancer is a significant global health issue, with chronic diseases and sedentary lifestyles contributing to its rise. Early detection is crucial for effective treatment, and economic strategies, such as telemedicine, are increasingly being employed to expand access to skilled physicians and novel technologies. Software technologies, like AI and machine learning, are revolutionizing diagnostics, from genetic mutation identification to molecular profiling and tumor sequencing. Telemedicine enables remote consultations, reducing hospital spending and personal healthcare spending. Companies like GE Healthcare and Viome Life Science are leading the way with innovative diagnostic devices, such as CancerDetect and advanced imaging technologies like PET/CT, CT, MRI, and endoscopy. Dental care plays a vital role in head and neck cancer detection, with biopsy, physical exams, and pathologists essential for accurate diagnosis. Reimbursement issues and diagnostic procedures, such as Thyroid nodule assessment and oropharyngeal cancer detection, continue to challenge the healthcare industry. Immunotherapy and targeted therapy are emerging treatment modes, with clinical trials ongoing to improve patient outcomes. Novel technologies, like genomic testing, are transforming cancer diagnosis and treatment, with economic strategies crucial for widespread adoption. Economic strategies, such as government subsidies and insurance coverage, will be essential to address the rising costs of cancer treatment and diagnostic procedures. Chronic diseases, such as throat cancer, pose a significant threat, with diagnostic imaging and biopsy essential for accurate diagnosis. Skilled physicians, radiologists, and pathologists are in high demand to interpret the vast amounts of data generated by these advanced diagnostic tools. In conclusion, the head and neck cancer diagnostics market is rapidly evolving, with economic strategies, software technologies, and novel diagnostic tools playing a crucial role in improving patient outcomes and reducing healthcare expenditure. Early detection, through initiatives like telemedicine and advanced diagnostic technologies, is essential for effective treatment and reducing the burden of cancer worldwide.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio